BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35733293)

  • 1. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
    Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
    Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.
    Shanmugalingam A; Hitos K; Hegde S; Al-Mashat A; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2022 May; 193(1):151-159. PubMed ID: 35229238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single centre experience in Turkey for comparison between core needle biopsy and surgical specimen evaluation results for HER2, SISH, estrogen receptors and progesterone receptors in breast cancer patients.
    Karaman H; Senel F; Tasdemir A; Özer I; Dogan M
    J Cancer Res Ther; 2022; 18(6):1789-1795. PubMed ID: 36412445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study on Level of Concordance Between Core Needle Biopsy and Surgical Specimen for Assessing Oestrogen Receptor, Progesterone Receptor, and Her2/Neu Receptor Status in Carcinoma Breast and Its Implications on Treatment Decisions.
    Damodaran D; Naidu BK; Varghese JC; Rajan P; Kuruvilla R; Kuruvilla S; Kavitha KP
    Indian J Surg Oncol; 2020 Sep; 11(3):446-450. PubMed ID: 33013125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
    Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
    Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
    BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
    Arnedos M; Nerurkar A; Osin P; A'Hern R; Smith IE; Dowsett M
    Ann Oncol; 2009 Dec; 20(12):1948-52. PubMed ID: 19570962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.
    Dekker TJ; Smit VT; Hooijer GK; Van de Vijver MJ; Mesker WE; Tollenaar RA; Nortier JW; Kroep JR
    Ann Oncol; 2013 Apr; 24(4):931-7. PubMed ID: 23211940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The appropriate number of preoperative core needle biopsy specimens for analysis in breast cancer.
    Sun T; Zhang H; Gao W; Yang Q
    Medicine (Baltimore); 2021 Apr; 100(14):e25400. PubMed ID: 33832135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?
    Greer LT; Rosman M; Mylander WC; Hooke J; Kovatich A; Sawyer K; Buras RR; Shriver CD; Tafra L
    J Am Coll Surg; 2013 Feb; 216(2):239-51. PubMed ID: 23141136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.